KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Share-based Compensation (2018 - 2025)

ClearPoint Neuro's Share-based Compensation history spans 13 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Share-based Compensation rose 6.2% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $7.9 million, up 17.12%, while the annual FY2024 figure was $6.9 million, 13.62% up from the prior year.
  • Share-based Compensation for Q3 2025 was $2.0 million at ClearPoint Neuro, down from $2.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.3 million in Q2 2025 and bottomed at $247000.0 in Q2 2021.
  • The 5-year median for Share-based Compensation is $1.5 million (2024), against an average of $1.3 million.
  • The largest annual shift saw Share-based Compensation increased 2.49% in 2021 before it soared 256.28% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $925000.0 in 2021, then grew by 26.7% to $1.2 million in 2022, then surged by 31.66% to $1.5 million in 2023, then rose by 10.37% to $1.7 million in 2024, then rose by 18.73% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Share-based Compensation are $2.0 million (Q3 2025), $2.3 million (Q2 2025), and $1.9 million (Q1 2025).